{"id":20562,"date":"2015-07-27T10:53:18","date_gmt":"2015-07-27T08:53:18","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=20562"},"modified":"2015-07-27T17:32:41","modified_gmt":"2015-07-27T15:32:41","slug":"negoziati-teva-con-allergan","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/negoziati-teva-con-allergan\/","title":{"rendered":"Israeli pharmaceutical company Teva acquires Allergan generics for 40.5 billion"},"content":{"rendered":"

\"Farmaci,AVIV, July 27<\/span> (Reuters)<\/span><\/a> \u2013 Teva Pharmaceutical Industries has agreed to purchase Allergan's generics business for $40.5 billion, of which $33.75 billion in cash, the remainder card-to-card, in a deal that will make the Israeli company one of the largest pharmaceutical groups in the world.<\/span><\/p>\n

Following the deal, the largest in Israeli corporate history, Teva promptly withdrew a hostile $40 billion offer for Mylan, a deal that was opposed by a Dutch foundation, a Mylan shareholder.<\/p>\n

The deal will also allow Dublin-based Allergan, the third largest US generic drug maker, to focus on brand-name drugs and reduce debt.<\/p>\n

The acquisition is just the latest in a growing wave of healthcare deals since early 2014. Globally, M&A in the industry has totaled $398.5 billion year-to-date through July 23. , the 80% more than a year earlier, according to Thomson Reuters data.<\/p>\n

On the site www.reuters.it other Reuters news in Italian. Top news also on www.twitter.com\/reuters_italia<\/p>\n

\u00a0_____________________________________________________________________<\/h3>\n

The Israeli could ask for Allergan generics.<\/h3>\n

THE\"\"Israeli generics maker Teva is in advanced talks with Allergan to acquire its generics business at 40.45bn $ according to Bloomberg<\/span><\/a>. The <\/span>voices<\/span><\/a> of a separation of generics, whose margins are only 50% (against 80% for products under patent), in a separate entity had been analyzed, as a precondition for a divestment and, in fact, the transaction could be announced this week.<\/span><\/p>\n

\"\"Allergan was bought last year by Actavis, which revived its name and created a $20 billion group of come in<\/a> . But generic drugs account for less than a third of sales and <allergan \u00e8 meglio conosciuta per Botox e Namenda contro il morbo di Alzheimer. Per Teva, che non \u00e8 riuscita finora a comprare Mylan pur offrendo 40 miliardi, sarebbe una via d\u2019uscita onorevole<\/p>\n

Les Echos.fr CATHERINE DUCRUET \/ JOURNALISTS<\/span> |

Related news: Farmac\u00eautica Allergan compra norte-americana Naurex por US$ 560 milh\u00f5es<\/a><\/span><\/p>\n

Pharmaceutical: Teva tries again with Mylan, upwards offer up to at least 43 billion $<\/span><\/a><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

AVIV, 27 luglio (Reuters) – Teva Pharmaceutical Industries ha concordato l’acquisto del business dei farmaci generici di Allergan per 40,5 miliardi di dollari, di cui 33,75 miliardi in contanti il resto carta contro carta, in un’operazione che far\u00e0 della societ\u00e0 israeliana uno dei maggiori gruppi farmaceutici al mondo. In seguito al deal, il maggiore nella …<\/p>","protected":false},"author":4,"featured_media":20566,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-20562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/20562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=20562"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/20562\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/20566"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=20562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=20562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=20562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}